Näytä suppeat kuvailutiedot

Predictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations

Baum Ulrike; Salo Heini; Auranen Kari; Leino Tuija; Lehtonen Toni

dc.contributor.authorBaum Ulrike
dc.contributor.authorSalo Heini
dc.contributor.authorAuranen Kari
dc.contributor.authorLeino Tuija
dc.contributor.authorLehtonen Toni
dc.date.accessioned2022-10-27T12:23:25Z
dc.date.available2022-10-27T12:23:25Z
dc.identifier.urihttps://www.utupub.fi/handle/10024/158271
dc.description.abstract<p>Introduction: The aim of this study was to investigate how age and underlying medical conditions affect the risk of severe outcomes following SARS-CoV-2 infection and how they should be weighed while prioritising vaccinations against COVID-19. <br></p><p>Methods: This population-based register study includes all SARS-CoV-2 PCR-test-positive cases until 24 Feb 2021, based on the Finnish National Infectious Diseases Register. The cases were linked to other registers to identify presence of predisposing factors and severe outcomes (hospitalisation, intensive care treatment, death). The odds of severe outcomes were compared in those with and without the pre-specified predisposing factors using logistic regression. Furthermore, population-based rates were compared between those with a given predisposing factor and those without any of the specified predisposing factors using negative binomial regression. <br></p><p>Results: Age and various comorbidities were found to be predictors of severe COVID-19. Compared to 60–69-year-olds, the odds ratio (OR) of death was 7.1 for 70–79-year-olds, 26.7 for 80–89-year-olds, and 55.8 for ≥ 90-year-olds. Among the 20–69-year-olds, chronic renal disease (OR 9.4), malignant neoplasms (5.8), hematologic malignancy (5.6), chronic pulmonary disease (5.4), and cerebral palsy or other paralytic syndromes (4.6) were strongly associated with COVID-19 mortality; severe disorders of the immune system (8.0), organ or stem cell transplant (7.2), chronic renal disease (6.7), and diseases of myoneural junction and muscle (5.5) were strongly associated with COVID-19 hospitalisation. Type 2 diabetes and asthma, two very common comorbidities, were associated with all three outcomes, with ORs from 2.1 to 4.3. The population-based rate of SARS-CoV-2 infection decreased with age. Taking the 60–69-year-olds as reference, the rate ratio was highest (3.0) for 20–29-year-olds and < 1 for 70–79-year-olds and 80–89-year-olds. <br></p><p>Conclusion: Comorbidities predispose for severe COVID-19 among younger ages. In vaccine prioritisation both the risk of infection and the risk of severe outcomes, if infected, should be considered. © 2022 The Authors</p><h3>Author keywords</h3><p>Chronically ill (max 6); COVID-19; Elderly; Risk factors; SARS-CoV-2</p>
dc.language.isoen
dc.publisherElsevier Ltd
dc.titlePredictors of hospitalisation and death due to SARS-CoV-2 infection in Finland: A population-based register study with implications to vaccinations
dc.identifier.urlhttps://doi.org/10.1016/j.vaccine.2022.04.055
dc.identifier.urnURN:NBN:fi-fe2022081153901
dc.relation.volume40
dc.contributor.organizationfi=tilastotiede|en=Statistics|
dc.contributor.organization-code2606103
dc.converis.publication-id175511636
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/175511636
dc.format.pagerange3355
dc.format.pagerange3345
dc.identifier.jour-issn0264-410X
dc.okm.affiliatedauthorAuranen, Kari
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.discipline3141 Health care scienceen_GB
dc.okm.discipline112 Tilastotiedefi_FI
dc.okm.discipline3142 Kansanterveystiede, ympäristö ja työterveysfi_FI
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3141 Terveystiedefi_FI
dc.okm.discipline112 Statistics and probabilityen_GB
dc.okm.discipline3142 Public health care science, environmental and occupational healthen_GB
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeJournal article
dc.publisher.countryAlankomaatfi_FI
dc.publisher.countryNetherlandsen_GB
dc.publisher.country-codeNL
dc.relation.doi10.1016/j.vaccine.2022.04.055
dc.relation.ispartofjournalVaccine
dc.relation.issue24
dc.year.issued2022


Aineistoon kuuluvat tiedostot

Thumbnail

Aineisto kuuluu seuraaviin kokoelmiin

Näytä suppeat kuvailutiedot